128.79 +0.06 (0.04%)
After hours: 4:26PM EDT
|Bid||128.89 x 1800|
|Ask||128.97 x 800|
|Day's Range||127.26 - 129.91|
|52 Week Range||103.00 - 149.07|
|Beta (3Y Monthly)||1.09|
|PE Ratio (TTM)||27.68|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||149.57|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Charles River earnings of $1.40 a share, on an adjusted basis, on $604.6 million in sales beat first-quarter estimates Tuesday. But shares closed down on worries of a China trade war.
Charles River (CRL) delivered earnings and revenue surprises of 1.45% and 0.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories International Inc NYSE:CRLView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for CRL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CRL. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.75 billion over the last one-month into ETFs that hold CRL are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The Wilmington, Massachusetts-based company said it had profit of $1.11 per share. Earnings, adjusted for non-recurring costs, came to $1.40 per share. The results surpassed Wall Street expectations. The ...
Pomerantz LLP is investigating claims on behalf of investors of Charles River Laboratories International, Inc. (“Charles River” or the “Company”) (NYSE: CRL). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. On April 30, 2019, Charles River disclosed that a “highly sophisticated, well-resourced intruder” accessed its information system in mid-March 2019, and that data belonging to “approximately 1% of Charles River’s total number of clients” was “known to have been copied”. Following this disclosure, Charles River’s stock price fell $5.11 per share, or 3.59%, over the following two trading sessions, closing at $137.41 per share on May 1, 2019. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.
An unidentified group of hackers recently broke into Charles River Laboratories’ information system and copied some drug developers’ data, the company disclosed Tuesday.
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Laboratories International, Inc. (CRL) announced today that it has completed the previously announced acquisition of Citoxlab for €448 million in cash (or approximately $500 million based on current exchange rates), subject to customary closing adjustments. Citoxlab is a premier, non-clinical contract research organization (CRO), specializing in regulated safety assessment services, non-regulated discovery services, and medical device testing. With operations in Europe and North America, the acquisition of Citoxlab will further strengthen Charles River’s position as the leading, global, early-stage CRO by expanding its scientific portfolio and geographic footprint, which will enhance the Company’s ability to partner with clients across the drug discovery and development continuum.
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E ratio and reflect on what it tells us about the...
Charles River Laboratories International, Inc. (CRL) will release first-quarter 2019 financial results on Tuesday, May 7th, before the market opens. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts.
Behind every patient stands thousands of scientists and researchers collaborating to develop life-saving drugs. Jenne’s story highlights the importance of that work.
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.